Mitochondrial transcription factor A contributes to cisplatin resistance in patients with estrogen receptor-positive breast cancer

Molecular Medicine Reports

Volumn 14, Issue 6, 2016, Pages 5304-5310

  Gao, Wei ^a   Wu, Mei Hong ^a   Wang, Ning ^a   Ying, Ming Zheng ^a   Zhang, Ying Yi ^a   Hua, Jing ^a   Chuan, Liu ^a   Wang, Ya Jie ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cisplatin resistance; Estrogen receptor; Mitochondrial transcription factor A

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; ESTROGEN RECEPTOR; MITOCHONDRIAL TRANSCRIPTION FACTOR A; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NRF1; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; MITOCHONDRIAL PROTEIN; NUCLEAR RESPIRATORY FACTOR 1; TFAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; BREAST TUMOR; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; NUCLEAR RESPIRATORY FACTOR 1; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84999232830     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5881     Document Type: Article

References (32)

1. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
2. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 8: 24-34, 2010.
3. Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, et al: Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer 136: 204-211, 2015.
4. Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
5. Yazlovitskaya EM and Persons DL: Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res 23: 2275-2279, 2003.
6. Wei Q, Dong G, Yang T, Megyesi J, Price PM and Dong Z: Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293: F1282-F1291, 2007.
7. Yoshida K, Ozaki T, Furuya K, Nakanishi M, Kikuchi H, Yamamoto H, Ono S, Koda T, Omura K and Nakagawara A: ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 27: 1183-1188, 2008.
8. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998.
9. Sui M, Zhang H and Fan W: The role of estrogen and estrogen receptors in chemoresistance. Curr Med Chem 18: 4674-4683, 2011.
10. Mattingly KA, Ivanova MM, Riggs KA, Wickramasinghe NS, Barch MJ and Klinge CM: Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. Mol Endocrinol 22: 609-622, 2008.
11. Cam H, Balciunaite E, Blais A, Spektor A, Scarpulla RC, Young R, Kluger Y and Dynlacht BD: A common set of gene regulatory networks links metabolism and growth inhibition. Mol Cell 16: 399-411, 2004.
12. Kang D, Kim SH and Hamasaki N: Mitochondrial transcription factor A (TFAM): Roles in maintenance of mtDNA and cellular functions. Mitochondrion 7: 39-44, 2007.
13. Hallberg BM and Larsson NG: TFAM forces mtDNA to make a U-turn. Nat Struct Mol Biol 18: 1179-1181, 2011.
14. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z and Cullen KJ: Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin Cancer Res 12: 5817-5825, 2006.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
16. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J and Narod SA: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115: 359-363, 2009.
17. Hsieh CY, Santell RC, Haslam SZ and Helferich WG: Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 58: 3833-3838, 1998.
18. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J and Gustafsson JA: Estrogen receptor beta inhibits 17beta-estradiolstimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101: 1566-1571, 2004.
19. Ferguson AT, Lapidus RG, Baylin SB and Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995.
20. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C and Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008, 2006.
21. Li L and Yu AQ: The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells. J Cancer Res Clin Oncol 141: 2071-2077, 2015.
22. Hosoya N and Miyagawa K: Targeting DNA damage response in cancer therapy. Cancer Sci 105: 370-388, 2014.
23. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
24. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153, 2010.
25. Funato T, Kozawa K, Kaku M and Sasaki T: Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. Anticancer Drugs 12: 829-834, 2001.
26. Fraser M, Bai T and Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122: 534-546, 2008.
27. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG and Carey TE: P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25: 654-661, 2003.
28. Niedner H, Christen R, Lin X, Kondo A and Howell SB: Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160, 2001.
29. Funato T, Kozawa K, Kaku M and Sasaki T: Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. Anticancer Drugs 12: 829-834, 2001.
30. Fraser M, Bai T and Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122: 534-546, 2008.
31. Olivero OA, Semino C, Kassim A, Lopez-Larraza DM and Poirier MC: Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 346: 221-230, 1995.
32. Kroemer G, Dallaporta B and Resche-Rigon M: The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619-642, 1998.